One-year follow-up of Coll2-1, Coll2-1NO<sub>2</sub>and myeloperoxydase serum levels in osteoarthritis patients after hip or knee replacement

Deberg, Michelle; Dubuc, Jean-Émile; Labasse, A; Sanchez, Christelle; Quettier, E.; Bosseloir, Alain; Crielaard, Jean-Michel; Henrotin, Yves

doi:10.1136/ard.2007.073452

Cited by 56 publications

(56 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study positioned Coll2-1 and Coll2-1 NO 2 biomarkers in the framework of biomarkers applied to the development of drugs intended for the treatment of OA as described in the recent published work by Kraus et al 35 Previous works reporting Coll2-1 and Coll2-1 NO 2 levels have fulfilled the step of exploration based on pre-clinical evidence [18][19][20][21][22] and the further step of demonstration giving evidence that support the primary clinical evidence in both healthy and OA patients. 16,17,23 The Coll2-1 AND Coll2-1 NO 2 LEVELS AFTER VISCOSUPPLEMENTATION 905 present study gave the first evidence to the next step of characterization. These steps have also equivalence in the nomenclature suggested in the guidance by the Federal Drug Administration.…”

Section: Discussionsupporting

confidence: 52%

“…16,17 These biomarkers have been validated in vivo in mouse, guinea pig and horse [18][19][20][21][22] and also in healthy human 16 and OA patients. 17,23 The aim of this study was to measure the evolution of the serum levels of Coll2-1 and Coll2-1 NO 2 in knee OA patients after VS. This study is part of the Biovisco study and this article is the continuation of the previous one which has reported the concentrations of the following biomarkers: CTXII, COMP, C 2 C, CS846, HA, PIICP.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Early decrease of serum biomarkers of type II collagen degradation (Coll2‐1) and joint inflammation (Coll2‐1 NO₂) by hyaluronic acid intra‐articular injections in patients with knee osteoarthritis: A research study part of the Biovisco study

Henrotin

Chevalier²,

Deberg³

et al. 2013

Journal Orthopaedic Research

View full text Add to dashboard Cite

To measure the evolution of the serum levels of specific Osteoarthritis (OA) biomarker, Coll2-1 and Coll2-1 NO 2 in knee osteoarthritic patients after viscosupplementation (VS). Fifty-one patients with unilateral symptomatic knee were recruited for this prospective open label study. They received three intra-articular injections of 2 ml of hyaluronic acid (Hylan GF-20) and were followed for 3 months. Walking pain was evaluated and serum samples were taken at each visit. Coll2-1 and Coll2-1 NO 2 were measured in the serum using specific immunoassays. Variations over time of each parameter and predictive factor of response were studied. Forty-five patients were analyzed. The serum concentrations of Coll2-1 and Coll2-1 NO 2 were significantly higher in KL III/IV patients compared to KL I/II patients at baseline and decreased systematically over time after VS. Its effect was ever more pronounced in patients with KL III/IV. The serum concentration of Coll2-1 was significantly lower at baseline in responders than in non-responders. This study suggests a rapid slowdown of type II collagen degradation and joint inflammation after VS with Hylan G-20 and gives additional information for the validation of accurate biomarkers for OA. The serum level of Coll2-1 appeared to be a predictive factor for response to treatment. ß

show abstract

Section: Discussionsupporting

confidence: 52%

mentioning

confidence: 99%

Early decrease of serum biomarkers of type II collagen degradation (Coll2‐1) and joint inflammation (Coll2‐1 NO₂) by hyaluronic acid intra‐articular injections in patients with knee osteoarthritis: A research study part of the Biovisco study

Henrotin

Chevalier²,

Deberg³

et al. 2013

Journal Orthopaedic Research

View full text Add to dashboard Cite

show abstract

“…Another new biomarker of cartilage damage is Fibulin-3, which in turn is derived from extracellular matrix proteins [20,21]. These biomarkers are correlated with the severity of OA, but in our study, urinary levels of Coll2-1, Coll2-1NO2 and Fibulin-3 were not reduced in any of the studied groups.…”

Section: Discussioncontrasting

confidence: 41%

Effects of Native Type II Collagen Treatment on Knee Osteoarthritis: A Randomized Controlled Trial

et al. 2016

View full text Add to dashboard Cite

Objective: The aim of this randomized controlled study was to evaluate the efficacy of oral native type II collagen treatment on the symptoms and biological markers of cartilage degradation, when given concomitantly with acetaminophen in patients with knee osteoarthritis. Materials and Methods:Thirty-nine patients diagnosed with knee osteoarthritis were included and randomly distributed into two groups: one treated with 1500 mg/day of acetaminophen (group AC; n=19) and the other treated with 1500 mg/day of acetaminophen plus 10 mg/day of native type II collagen (group AC+CII; n=20) for 3 months. Visual Analogue Scale (VAS) at rest and during walking, Western Ontario McMaster (WOMAC) pain, WOMAC function, and Short Form-36 (SF-36) scores, were recorded. Coll2-1, Coll2-1NO2 and Fibulin-3 levels were quantified in urine as biomarkers of disease progression. ClinicalTrials.gov: NCT02237989.Results: After 3 months of treatment, significant improvements compared to baseline were reported in joint pain (VAS walking), function (WOMAC) and quality of life (SF-36) in the AC+CII group, while only improvements in some subscales of the SF-36 survey and VAS walking were detected in the AC group. Comparisons between the groups revealed a significant difference in VAS walking score in favour of the AC+CII group as compared to AC group. Biochemical markers of cartilage degradation in urine did not significantly improve in any of the groups. Conclusion:All in all, these results suggest that native type II collagen treatment combined with acetaminophen is superior to only acetaminophen for symptomatic treatment of patients with knee osteoarthritis.

show abstract

“…These results are in agreement with previous studies by Yazici et al [10] and Baskol et al [12] , who observed a relationship between MPO and biomarkers of inflammatory activity (CRP, ESR and WBC). Steinbeck et al [4] reported that patients with early osteoarthritis displayed high levels of MPO, whereas Deber et al [32] found that serum MPO levels decreased after joint replacement, indicating that neutrophil activation occurs in osteoarthritic joints, even in late stages of the disease.…”

Section: Discussionmentioning

confidence: 99%

Infliximab Reduces Myeloperoxidase Concentration in Chronic Inflammatory Joint Diseases

et al. 2009

View full text Add to dashboard Cite

The present study evaluated the effect of infliximab on the myeloperoxidase (MPO) concentration in chronic inflammatory joint disease. Eighteen patients were divided into active and inactive groups. Erythrocyte sedimentation rate, C-reactive protein, white blood cell counts, MPO concentration, and biomarkers of oxidative stress were measured before and after the infusion of infliximab. Patients with active disease showed increases in concentrations of MPO and biomarkers of oxidation, but decreases in antioxidant parameters. After infliximab treatment, both inflammatory parameters and MPO concentrations were normalized. In conclusion: (1) the MPO concentration is related to inflammatory activity and could play an important role in the maintenance and outbreak of oxidative stress present in these diseases, and (2) infliximab inhibits MPO concentration.

show abstract

One-year follow-up of Coll2-1, Coll2-1NO₂and myeloperoxydase serum levels in osteoarthritis patients after hip or knee replacement

Cited by 56 publications

References 44 publications

Early decrease of serum biomarkers of type II collagen degradation (Coll2‐1) and joint inflammation (Coll2‐1 NO₂) by hyaluronic acid intra‐articular injections in patients with knee osteoarthritis: A research study part of the Biovisco study

Early decrease of serum biomarkers of type II collagen degradation (Coll2‐1) and joint inflammation (Coll2‐1 NO₂) by hyaluronic acid intra‐articular injections in patients with knee osteoarthritis: A research study part of the Biovisco study

Effects of Native Type II Collagen Treatment on Knee Osteoarthritis: A Randomized Controlled Trial

Infliximab Reduces Myeloperoxidase Concentration in Chronic Inflammatory Joint Diseases

Contact Info

Product

Resources

About

One-year follow-up of Coll2-1, Coll2-1NO2and myeloperoxydase serum levels in osteoarthritis patients after hip or knee replacement

Cited by 56 publications

References 44 publications

Early decrease of serum biomarkers of type II collagen degradation (Coll2‐1) and joint inflammation (Coll2‐1 NO2) by hyaluronic acid intra‐articular injections in patients with knee osteoarthritis: A research study part of the Biovisco study

Early decrease of serum biomarkers of type II collagen degradation (Coll2‐1) and joint inflammation (Coll2‐1 NO2) by hyaluronic acid intra‐articular injections in patients with knee osteoarthritis: A research study part of the Biovisco study

Effects of Native Type II Collagen Treatment on Knee Osteoarthritis: A Randomized Controlled Trial

Infliximab Reduces Myeloperoxidase Concentration in Chronic Inflammatory Joint Diseases

Contact Info

Product

Resources

About

One-year follow-up of Coll2-1, Coll2-1NO₂and myeloperoxydase serum levels in osteoarthritis patients after hip or knee replacement

Early decrease of serum biomarkers of type II collagen degradation (Coll2‐1) and joint inflammation (Coll2‐1 NO₂) by hyaluronic acid intra‐articular injections in patients with knee osteoarthritis: A research study part of the Biovisco study

Early decrease of serum biomarkers of type II collagen degradation (Coll2‐1) and joint inflammation (Coll2‐1 NO₂) by hyaluronic acid intra‐articular injections in patients with knee osteoarthritis: A research study part of the Biovisco study